Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin

Phase 1 Completed 56 enrolled Guangdong Raynovent Biotech Co., Ltd

RandomizedSequentialOpen-labelBasic science

Summary

The drug-drug interaction study had been designed to investigate the effect of Leritrelvir on the pharmacokinetics of Midazolam, Omeprazole, Rosuvastatin and the effect of Verapamil and Rifampin on the pharmacokinetics of Leritrelvir

Timeline

Start: 2023-09-01
Primary completion: 2023-11-01
Completion: 2023-12-31

Publications

Peng J, Chen J, Du XX, Li HJ, Qin RZ, Chen SH, Liu X, Cheng Q, Li XM, Huang DX, Duan L, Li MY, Wu WZ, Ye LK, Li YY, Xie ZH, Han K. Pharmacokinetic Drug-Drug Interaction of Leritrelvir in Healthy Chinese Volunteers: A Single-Arm, Open-Label, Dual-Cohort Study. Clin Drug Investig. 2026 Jun;46(6):609-618. doi: 10.1007/s40261-026-01556-w. Epub 2026 May 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leritrelvir	Unknown	400 mg	Oral
Subject	Leritrelvir	Unknown	2400 mg	Oral
Subject	Midazolam	Small molecule	15 mg	Oral
Subject	Omeprazole	Other / unclassified	20 mg	Oral
Subject	Rifampin	Small molecule	4800 mg	Oral
Subject	Rosuvastatin	Small molecule	10 mg	Oral
Subject	Verapamil	Other / unclassified	1200 mg	Oral

Indications

No indication recorded.